Search
Search
Carl D. Regillo, MD, FACS, David A. Eichenbaum, MD, and Anat Loewenstein, MD, MHA
Show Description +
Carl D. Regillo, MD, FACS, is joined by David A. Eichenbaum, MD, and Anat Loewenstein, MD, MHA, to discuss feedback that OcuTerra has received about topical therapies it is developing for the treatment of diabetic retinopathy. They explain how preclinical and phase 1b data show efficacy for transmembrane permeability through the sclera.
Posted: 9/06/2023
Carl D. Regillo, MD, FACS, David A. Eichenbaum, MD, and Anat Loewenstein, MD, MHA
Carl D. Regillo, MD, FACS, is joined by David A. Eichenbaum, MD, and Anat Loewenstein, MD, MHA, to discuss feedback that OcuTerra has received about topical therapies it is developing for the treatment of diabetic retinopathy. They explain how preclinical and phase 1b data show efficacy for transmembrane permeability through the sclera.
Posted: 9/06/2023
Current Practice and Future Options for Nonproliferative Diabetic Retinopathy
DR Research Roundup: Phase 2 and 3
Shifting the Paradigm
Current Practice and Future Options for Nonproliferative Diabetic Retinopathy
To find out more about the phase 2 DREAM study of OTT166 in eyes with diabetic retinopathy and how you can refer your patients, please contact the representative from Parexel, the CRO assisting OcuTerra in facilitating the DREAM study, listed below.
Learn MoreAbout Ocuterra
OcuTerra is led by a team with significant biotechnology entrepreneurial and ophthalmology drug development experience and supported by the field’s leading scientific and clinical advisors.
Visit us online: ocuterratx.com
Follow Ocuterra
© 2023 OcuTerra Therapeutics, Inc.
